These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 1309466)

  • 1. Single lung transplantation. Factors in postoperative cytomegalovirus infection.
    Calhoon JH; Nichols L; Davis R; Bryant CL; Levine SM; Zamora CA; Anzueta A; Lum CT; Grover FL; Trinkle JK
    J Thorac Cardiovasc Surg; 1992 Jan; 103(1):21-5; discussion 25-6. PubMed ID: 1309466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. OKT3 induction and steroid-free maintenance immunosuppression for treatment of high-risk heart transplant recipients.
    Prieto M; Lake KD; Pritzker MR; Jorgensen CR; Arom KV; Love KR; Emery RW
    J Heart Lung Transplant; 1991; 10(6):901-11. PubMed ID: 1661608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 20-year follow-up results of a randomized controlled trial comparing antilymphocyte globulin induction to no induction in renal transplant patients.
    Cantarovich M; Durrbach A; Hiesse C; Ladouceur M; Benoit G; Charpentier B
    Transplantation; 2008 Dec; 86(12):1732-7. PubMed ID: 19104413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Should heart-lung transplant donors and recipients be matched according to cytomegalovirus serologic status?
    Novick RJ; Menkis AH; McKenzie FN; Reid KR; Ahmad D
    J Heart Transplant; 1990; 9(6):699-706. PubMed ID: 2177496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylaxis and management of cytomegalovirus pneumonitis after lung transplantation: a review of experience in one center.
    Gould FK; Freeman R; Taylor CE; Ashcroft T; Dark JH; Corris PA
    J Heart Lung Transplant; 1993; 12(4):695-9. PubMed ID: 8396437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined antiviral and immunoglobulin therapy as prophylaxis against cytomegalovirus infection after heart transplantation.
    Valenza M; Czer LS; Pan SH; Aleksic I; Freimark D; Harasty DA; Admon D; Barath P; Blanche C; Trento A
    J Heart Lung Transplant; 1995; 14(4):659-65. PubMed ID: 7578172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of immunosuppressive regimen on the incidence and characteristics of cytomegalovirus infection in heart transplantation: a single-center experience with preemptive therapy.
    De Santo LS; Romano G; Mastroianni C; Roberta C; Della Corte A; Amarelli C; Maiello C; Giannolo B; Marra C; Ragone E; Grimaldi M; Utili R; Scardone M; Cotrufo M
    Transplant Proc; 2005; 37(6):2684-7. PubMed ID: 16182784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytomegalovirus after heart transplantation. Risk factors for infection and death: a multiinstitutional study. The Cardiac Transplant Research Database Group.
    Kirklin JK; Naftel DC; Levine TB; Bourge RC; Pelletier GB; O'Donnell J; Miller LW; Pritzker MR
    J Heart Lung Transplant; 1994; 13(3):394-404. PubMed ID: 8061014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of cytolytic therapy on bronchiolitis obliterans syndrome.
    Date H; Lynch JP; Sundaresan S; Patterson GA; Trulock EP
    J Heart Lung Transplant; 1998 Sep; 17(9):869-75. PubMed ID: 9773858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term renal graft function and survival in patients with high-risk for cytomegalovirus infection receiving preemptive therapy.
    Alberú J; Morales-Buenrostro LE; Correa-Rotter R; Muñoz-Trejo T; Zúñiga-Varga J; Cuéllar-González JV; Mayorga-Madrigal H; Vanegas-Carrero R; Aranda F; Rodríguez-Romo R; Herrera-Garcia C; González-Michaca L; Sierra-Madero JG
    Rev Invest Clin; 2008; 60(5):365-74. PubMed ID: 19227433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized study comparing deflazacort and prednisone in heart transplant patients.
    Arizón JM; Anguita M; Vallés F; López-Rubio F; López-Granados A; Casares J; Segura J; Mesa D; Muñoz I; Alados P
    J Heart Lung Transplant; 1993; 12(5):864-8. PubMed ID: 8241229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delayed development of obliterative bronchiolitis syndrome with OKT3 after unilateral lung transplantation. A plea for multicenter immunosuppressive trials.
    Ross DJ; Jordan SC; Nathan SD; Kass RM; Koerner SK
    Chest; 1996 Apr; 109(4):870-3. PubMed ID: 8635362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylactic therapy for rejection after cardiac transplantation. A comparison of rabbit antithymocyte globulin and OKT3.
    Kirklin JK; Bourge RC; White-Williams C; Naftel DC; Thomas FT; Thomas JM; Phillips MG
    J Thorac Cardiovasc Surg; 1990 Apr; 99(4):716-24. PubMed ID: 2108282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction therapy with cyclosporine without cytolytic agents results in a low incidence of acute rejection without significant renal impairment in heart transplant patients.
    Jazzar A; Fagiuoli S; Sisson S; Zuhdi N; Cooper DK
    Clin Transplant; 1995 Aug; 9(4):334-9. PubMed ID: 7579743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of cytomegalovirus infection and acute rejection after allogeneic lung transplantation in the rat: virus-induced expression of major histocompatibility complex class II antigens.
    You XM; Steinmüller C; Wagner TO; Bruggeman CA; Haverich A; Steinhoff G
    J Heart Lung Transplant; 1996 Nov; 15(11):1108-19. PubMed ID: 8956120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefits of avoidance of induction immunosuppression in heart transplantation.
    Menkis AH; McKenzie FN; Thomson D; Jones M; Pflugfelder P; Kostuk WJ; Stiller CR
    J Heart Transplant; 1989; 8(4):311-4. PubMed ID: 2671316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of infectious complications following heart transplantation with triple-drug immunotherapy.
    Andreone PA; Olivari MT; Elick B; Arentzen CE; Sibley RK; Bolman RM; Simmons RL; Ring WS
    J Heart Transplant; 1986; 5(1):13-9. PubMed ID: 3302153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus prophylaxis with ganciclovir, acyclovir, and CMV hyperimmune globulin in liver transplant patients receiving OKT3 induction.
    Ham JM; Shelden SL; Godkin RR; Posner MP; Fisher RA
    Transplant Proc; 1995 Oct; 27(5 Suppl 1):31-3. PubMed ID: 7482814
    [No Abstract]   [Full Text] [Related]  

  • 19. Infectious complications in kidney transplant recipients: a single-center experience.
    Charfeddine K; Zaghden S; Kharrat M; Kamoun K; Jarraya F; Hachicha J
    Transplant Proc; 2005; 37(6):2823-5. PubMed ID: 16182820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectivity of a T-cell-adapted induction therapy with anti-thymocyte globulin (Sangstat).
    Koch A; Daniel V; Dengler TJ; Schnabel PA; Hagl S; Sack FU
    J Heart Lung Transplant; 2005 Jun; 24(6):708-13. PubMed ID: 15949731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.